NO2324113T3 - - Google Patents
Info
- Publication number
- NO2324113T3 NO2324113T3 NO09805653A NO09805653A NO2324113T3 NO 2324113 T3 NO2324113 T3 NO 2324113T3 NO 09805653 A NO09805653 A NO 09805653A NO 09805653 A NO09805653 A NO 09805653A NO 2324113 T3 NO2324113 T3 NO 2324113T3
- Authority
- NO
- Norway
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8750408P | 2008-08-08 | 2008-08-08 | |
| US21860309P | 2009-06-19 | 2009-06-19 | |
| PCT/US2009/053249 WO2010017542A1 (fr) | 2008-08-08 | 2009-08-10 | Particules similaires à un virus comportant des séquences d'acides aminés de capside composites pour une réactivité croisée améliorée |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO2324113T3 true NO2324113T3 (fr) | 2018-07-28 |
Family
ID=41664003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO09805653A NO2324113T3 (fr) | 2008-08-08 | 2009-08-10 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8841120B2 (fr) |
| EP (2) | EP3382011A1 (fr) |
| JP (3) | JP5852883B2 (fr) |
| KR (2) | KR101793161B1 (fr) |
| CN (2) | CN104911154A (fr) |
| AU (1) | AU2009279456B2 (fr) |
| CA (1) | CA2733589C (fr) |
| DK (1) | DK2324113T3 (fr) |
| ES (1) | ES2668836T3 (fr) |
| HK (1) | HK1215051A1 (fr) |
| NO (1) | NO2324113T3 (fr) |
| PL (1) | PL2324113T3 (fr) |
| SG (1) | SG2013057732A (fr) |
| WO (1) | WO2010017542A1 (fr) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5683811B2 (ja) * | 2006-07-27 | 2015-03-11 | タケダ ヴァクシーンズ， インコーポレイテッド | キメラインフルエンザウイルス様粒子 |
| ES2577833T3 (es) | 2006-09-29 | 2016-07-19 | Takeda Vaccines, Inc. | Formulaciones de vacuna para norovirus |
| HUE028605T2 (en) | 2007-03-14 | 2016-12-28 | Takeda Vaccines Inc | Cleaning virus-like particles |
| US20100266636A1 (en) | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
| SG10201601660YA (en) | 2007-09-18 | 2016-04-28 | Takeda Vaccines Inc | Method of conferring a protective immune response to norovirus |
| KR101793161B1 (ko) | 2008-08-08 | 2017-11-03 | 다케다 백신즈 인코포레이티드 | 강화된 교차 반응성을 가진 복합체 캡시드 아미노산 서열들을 포함하는 바이러스-유사 입자들 |
| US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
| CA2804501C (fr) | 2010-07-06 | 2021-01-26 | Novartis Ag | Compositions immunogenes derivees d'un norovirus et methodes |
| EP3299030B1 (fr) | 2011-07-11 | 2022-06-08 | Takeda Vaccines, Inc. | Formulations de vaccin parentéral contre un norovirus |
| ES2655051T3 (es) | 2011-08-26 | 2018-02-16 | Wisconsin Alumni Research Foundation | Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas |
| JP6567824B2 (ja) * | 2011-10-12 | 2019-08-28 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | ヒトパピローマウイルスのワクチンおよびその使用方法 |
| JOP20130186B1 (ar) | 2012-06-22 | 2021-08-17 | Takeda Vaccines Montana Inc | تنقية الجزيئات الشبيهة بالفيروسات |
| AU2014248535B2 (en) | 2013-03-12 | 2017-03-30 | Inovio Pharmaceuticals, Inc. | Improved vaccines for human papilloma virus and methods for using the same |
| JP2015015931A (ja) | 2013-07-12 | 2015-01-29 | 株式会社Ｕｍｎファーマ | ウイルス様粒子を含む培養物の製造方法 |
| JP6479305B2 (ja) | 2013-07-12 | 2019-03-06 | 株式会社Ｕｍｎファーマ | ウイルス様粒子の精製方法 |
| US10524493B2 (en) * | 2013-09-16 | 2020-01-07 | The Johns Hopkins University | Compositions and methods for preventing or relieving symptoms of infections |
| AU2014329403B2 (en) | 2013-10-03 | 2020-10-08 | Takeda Vaccines, Inc. | Methods of detection and removal of rhabdoviruses from cell lines |
| CN112057613A (zh) * | 2013-11-29 | 2020-12-11 | 宾夕法尼亚大学理事会 | MERS-CoV疫苗 |
| WO2015196150A2 (fr) | 2014-06-20 | 2015-12-23 | Wisconsin Alumni Research Foundation (Warf) | Mutations conférant une stabilité génétique à des gènes supplémentaires dans des virus de la grippe |
| CA3000329A1 (fr) | 2015-08-28 | 2017-03-09 | Ology Bioservices, Inc. | Vaccin contre un norovirus |
| EP3341018B1 (fr) * | 2015-08-28 | 2026-05-20 | Wisconsin Alumni Res Found | Generation de virus de la grippe infectieux a partir des particules de type virus |
| US10513541B2 (en) * | 2015-12-04 | 2019-12-24 | Xiamen University | Mutant of L1 protein of human papillomavirus type 11 |
| CN109477074B (zh) | 2016-02-19 | 2023-01-24 | 威斯康星旧生研究基金会 | 用于疫苗开发的改进的乙型流感病毒复制 |
| CN110073005A (zh) | 2016-06-03 | 2019-07-30 | 奎斯特诊断投资有限责任公司 | 检测诺如病毒的方法 |
| US11608361B2 (en) | 2017-03-23 | 2023-03-21 | Medicago Inc. | Norovirus fusion proteins and VLPS comprising norovirus fusion proteins |
| EP3604540A4 (fr) | 2017-03-31 | 2020-12-23 | The University of Tokyo | Anticorps de norovirus |
| JP6795468B2 (ja) * | 2017-07-14 | 2020-12-02 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | ヒトパピローマウイルスのワクチンおよびその使用方法 |
| US11566050B2 (en) | 2017-10-18 | 2023-01-31 | The University Of North Carolina At Chapel Hill | Methods and compositions for norovirus vaccines and diagnostics |
| WO2019084310A1 (fr) | 2017-10-25 | 2019-05-02 | Yoshihiro Kawaoka | Virus de la grippe recombinants à ha stabilisé pour la réplication dans des oeufs |
| CN109776657B (zh) * | 2017-11-14 | 2021-11-26 | 北京康乐卫士生物技术股份有限公司 | 重组诺如病毒vlp颗粒和制备方法及其用途 |
| WO2019104439A1 (fr) * | 2017-11-30 | 2019-06-06 | Medicago Inc. | Protéines vp1 de norovirus modifiées et protéines vp1 de norovirus comprenant des vlp |
| US11918646B2 (en) | 2017-12-11 | 2024-03-05 | Board Of Regents, The University Of Texas System | Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration |
| WO2019233415A1 (fr) * | 2018-06-04 | 2019-12-12 | 厦门大学 | Mutant de la protéine l1 du papillomavirus humain 39 |
| KR102075393B1 (ko) * | 2018-06-28 | 2020-02-11 | 한국과학기술원 | 중증 열성 혈소판 감소 증후군(sfts) 바이러스 감염 질환 예방 또는 치료용 백신 조성물 |
| WO2020010428A1 (fr) * | 2018-07-13 | 2020-01-16 | Medicago Inc. | Protéines vp1 de norovirus modifiées et vlp comprenant des protéines vp1 de norovirus |
| JP7783047B2 (ja) | 2018-08-07 | 2025-12-09 | ウィスコンシン アルムニ リサーチ ファンデイション | 組換えの生物学的に封じ込められたフィロウイルスワクチン |
| EP3840780A1 (fr) | 2018-08-20 | 2021-06-30 | Wisconsin Alumni Research Foundation | Vecteurs pour induire des réponses immunitaires à des épitopes non dominants dans la protéine hémagglutinine (ha) |
| US20210308249A1 (en) | 2018-08-20 | 2021-10-07 | Takeda Vaccines, Inc. | Vlp formulations |
| AR117462A1 (es) * | 2018-12-20 | 2021-08-04 | Takeda Vaccines Inc | Vacuna contra norovirus, formulaciones y métodos |
| WO2020163804A1 (fr) | 2019-02-08 | 2020-08-13 | Wisconsin Alumni Research Foundation (Warf) | Lignée cellulaire humanisée |
| CN114929269A (zh) | 2019-05-01 | 2022-08-19 | 威斯康星校友研究基金会(Warf) | 用于疫苗开发的改进的流感病毒复制 |
| JP7627911B2 (ja) | 2019-08-27 | 2025-02-07 | ウィスコンシン アルムニ リサーチ ファンデイション | 卵内複製のための安定化されたｈａを持つ組換えインフルエンザウイルス |
| JP7075130B2 (ja) * | 2019-10-25 | 2022-05-25 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | ヒトパピローマウイルスのワクチンおよびその使用方法 |
| EP4093415A1 (fr) | 2020-01-24 | 2022-11-30 | Wisconsin Alumni Research Foundation (WARF) | Virus de la grippe recombinants à na stabilisé |
| US12290562B2 (en) | 2020-03-25 | 2025-05-06 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
| CN114316033A (zh) * | 2020-09-29 | 2022-04-12 | 香港理工大学深圳研究院 | 一种特异性识别诺如病毒的单克隆抗体及制备方法与应用 |
| EP4273155A4 (fr) * | 2020-12-30 | 2025-03-12 | Grand Theravac Life Science (Nanjing) Co., Ltd. | Pseudo-particule virale de norovirus, composition ou kit immunitaire et utilisation associée |
| US20240241122A1 (en) * | 2021-05-20 | 2024-07-18 | Denka Company Limited | Anti-norovirus antibody |
| EP4340874A1 (fr) | 2021-05-21 | 2024-03-27 | Takeda Vaccines, Inc. | Composition solide, procédé de lyophilisation et flacon de verre |
| EP4413033A1 (fr) | 2021-10-04 | 2024-08-14 | Takeda Vaccines, Inc. | Méthodes de détermination d'anticorps réagissant aux norovirus |
| EP4499138A4 (fr) * | 2022-03-25 | 2026-04-08 | Merck Sharp & Dohme Llc | Préparation de vaccin à libération contrôlée |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6572862B1 (en) | 1989-11-08 | 2003-06-03 | Baylor College Of Medicine | Methods and reagents to detect and characterize Norwalk and related viruses |
| AU1893592A (en) | 1991-03-25 | 1992-10-21 | Board Of Trustees Of The Leland Stanford Junior University | Norwalk virus human gastroenteritis agent and molecular cloning of corresponding cdnas |
| CA2133339A1 (fr) * | 1992-04-08 | 1993-10-09 | Jennifer S. Rota | Glycoproteines du virus morbilleux sauvage : vaccin et methode de depistage |
| JPH08500250A (ja) | 1992-09-07 | 1996-01-16 | ベイラー・カレッジ・オブ・メディシン | ノーウォークおよび関連ウイルスを検出し、かつ特徴付けるための方法並びに試薬 |
| US5788970A (en) * | 1994-03-29 | 1998-08-04 | The University Of Maryland College Park | Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon |
| ATE328068T1 (de) * | 1994-05-16 | 2006-06-15 | Merck & Co Inc | Papillomavirus vakzine |
| US5645051A (en) | 1995-04-21 | 1997-07-08 | Dura Pharmaceuticals, Inc. | Unit dose dry powder inhaler |
| US5861241A (en) | 1995-08-16 | 1999-01-19 | University Of Massachusetts | Monoclonal antibodies for detecting Norwalk virus |
| GB9525083D0 (en) | 1995-12-07 | 1996-02-07 | Danbiosyst Uk | Vaccine compositions |
| US5953727A (en) * | 1996-10-10 | 1999-09-14 | Incyte Pharmaceuticals, Inc. | Project-based full-length biomolecular sequence database |
| US6491919B2 (en) | 1997-04-01 | 2002-12-10 | Corixa Corporation | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
| WO1998050071A1 (fr) * | 1997-05-01 | 1998-11-12 | Chiron Corporation | Utilisation de particules de type viral en tant qu'adjuvants |
| US20040265377A1 (en) | 1997-10-27 | 2004-12-30 | Harry Seager | Solid dispersing vaccine composition for oral delivery |
| PL347472A1 (en) | 1998-08-14 | 2002-04-08 | Merck & Co Inc | Process for purifying human papillomavirus virus-like particles |
| AU770809B2 (en) | 1998-12-17 | 2004-03-04 | Merck Sharp & Dohme Corp. | Synthetic virus-like particles with heterologous epitopes |
| EP1186890B1 (fr) | 1999-06-22 | 2013-01-02 | Japan as Represented by Director-General of National Institute of Infectious Diseases | Materiel de detection de srsv |
| JP2002020399A (ja) | 2000-07-10 | 2002-01-23 | Osaka Prefecture | ノルウォークウイルス（ｎｖ）を認識するモノクローナル抗体 |
| US7041500B2 (en) | 2002-02-14 | 2006-05-09 | Novavax, Inc. | Insect cell line |
| BR0311995A (pt) * | 2002-06-20 | 2005-04-05 | Cytos Biotechnology Ag | Partìculas semelhantes a vìrus empacotadas para o uso como adjuvantes: método de preparação e uso |
| US7879338B2 (en) | 2003-07-21 | 2011-02-01 | Boyce Thompson Institute For Plant Research | Vectors and methods for immunization against norovirus using transgenic plants |
| US20050152911A1 (en) * | 2003-09-24 | 2005-07-14 | Montana State University | Norovirus monoclonal antibodies and peptides |
| WO2005037223A2 (fr) | 2003-10-15 | 2005-04-28 | Brigham And Women's Hospital, Inc. | Methodes et compositions d'immunomodulation |
| US20050215501A1 (en) | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
| FR2863890B1 (fr) | 2003-12-19 | 2006-03-24 | Aventis Pasteur | Composition immunostimulante |
| US7481997B1 (en) * | 2004-02-12 | 2009-01-27 | Montana State University | Snow mountain virus genome sequence, virus-like particles and methods of use |
| US20050260225A1 (en) | 2004-05-18 | 2005-11-24 | Goldberg Joanna B | Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens |
| CU23496A1 (es) * | 2004-09-03 | 2010-02-23 | Ct Ingenieria Genetica Biotech | Composición vacunal contra el virus de la hepatitis c |
| WO2006044857A2 (fr) | 2004-10-20 | 2006-04-27 | Acambis Inc. | Vaccins contre le virus de l'encephalite japonaise et le virus du nil occidental |
| GB0428394D0 (en) | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
| US8168771B2 (en) * | 2005-01-31 | 2012-05-01 | The Johns Hopkins University | Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants |
| JP2008530245A (ja) | 2005-02-18 | 2008-08-07 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド | 尿路病原性菌株由来の抗原 |
| PL1868642T3 (pl) | 2005-03-18 | 2013-10-31 | Cytos Biotechnology Ag | Białka fuzyjne alergenów kocich i ich zastosowania |
| EP1736538A1 (fr) | 2005-06-21 | 2006-12-27 | Cytos Biotechnology AG | Procédé pour la purification préparative de particules pseudo-virales (VLPs) |
| JP4825958B2 (ja) * | 2005-08-10 | 2011-11-30 | 財団法人ヒューマンサイエンス振興財団 | 高リスク群ヒトパピローマウイルスの中和抗体を誘導する抗原 |
| AU2006335256B2 (en) * | 2005-11-22 | 2012-10-18 | Novartis Vaccines And Diagnostics, Inc. | Norovirus and sapovirus antigens |
| JP2007145775A (ja) * | 2005-11-29 | 2007-06-14 | Falco Life Science:Kk | ノロウイルスｇｉの高感度検出方法 |
| ES2577833T3 (es) | 2006-09-29 | 2016-07-19 | Takeda Vaccines, Inc. | Formulaciones de vacuna para norovirus |
| SG10201601660YA (en) | 2007-09-18 | 2016-04-28 | Takeda Vaccines Inc | Method of conferring a protective immune response to norovirus |
| US20100266636A1 (en) | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
| KR101793161B1 (ko) | 2008-08-08 | 2017-11-03 | 다케다 백신즈 인코포레이티드 | 강화된 교차 반응성을 가진 복합체 캡시드 아미노산 서열들을 포함하는 바이러스-유사 입자들 |
| CA2787666A1 (fr) * | 2010-01-21 | 2011-07-28 | Ligocyte Pharmaceuticals, Inc. | Presentation d'antigenes heterologues cibles sur des pseudo-particules virales du calicivirus |
-
2009
- 2009-08-10 KR KR1020117005478A patent/KR101793161B1/ko active Active
- 2009-08-10 EP EP18158843.5A patent/EP3382011A1/fr active Pending
- 2009-08-10 CN CN201510127943.5A patent/CN104911154A/zh active Pending
- 2009-08-10 SG SG2013057732A patent/SG2013057732A/en unknown
- 2009-08-10 WO PCT/US2009/053249 patent/WO2010017542A1/fr not_active Ceased
- 2009-08-10 NO NO09805653A patent/NO2324113T3/no unknown
- 2009-08-10 ES ES09805653.4T patent/ES2668836T3/es active Active
- 2009-08-10 PL PL09805653T patent/PL2324113T3/pl unknown
- 2009-08-10 CN CN200980139886.5A patent/CN102177233B/zh active Active
- 2009-08-10 JP JP2011522301A patent/JP5852883B2/ja active Active
- 2009-08-10 CA CA2733589A patent/CA2733589C/fr active Active
- 2009-08-10 AU AU2009279456A patent/AU2009279456B2/en active Active
- 2009-08-10 EP EP09805653.4A patent/EP2324113B8/fr active Active
- 2009-08-10 DK DK09805653.4T patent/DK2324113T3/en active
- 2009-08-10 KR KR1020177030841A patent/KR102118458B1/ko active Active
-
2011
- 2011-02-08 US US13/023,363 patent/US8841120B2/en active Active
-
2014
- 2014-07-25 US US14/341,375 patent/US9518096B2/en active Active
-
2015
- 2015-04-02 JP JP2015075955A patent/JP6448445B2/ja active Active
-
2016
- 2016-03-16 HK HK16103047.9A patent/HK1215051A1/zh unknown
-
2017
- 2017-05-15 JP JP2017096499A patent/JP2017153484A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011530295A (ja) | 2011-12-22 |
| US20150023995A1 (en) | 2015-01-22 |
| PL2324113T3 (pl) | 2018-08-31 |
| JP2015171363A (ja) | 2015-10-01 |
| AU2009279456A1 (en) | 2010-02-11 |
| JP5852883B2 (ja) | 2016-02-03 |
| KR101793161B1 (ko) | 2017-11-03 |
| CN102177233B (zh) | 2015-04-15 |
| CA2733589C (fr) | 2021-07-13 |
| CA2733589A1 (fr) | 2010-02-11 |
| EP2324113B1 (fr) | 2018-02-28 |
| EP2324113A1 (fr) | 2011-05-25 |
| CN104911154A (zh) | 2015-09-16 |
| JP2017153484A (ja) | 2017-09-07 |
| ES2668836T3 (es) | 2018-05-22 |
| KR102118458B1 (ko) | 2020-06-03 |
| KR20170122848A (ko) | 2017-11-06 |
| HK1215051A1 (zh) | 2016-08-12 |
| AU2009279456A2 (en) | 2011-03-31 |
| US8841120B2 (en) | 2014-09-23 |
| EP2324113A4 (fr) | 2012-01-04 |
| KR20110053994A (ko) | 2011-05-24 |
| SG2013057732A (en) | 2015-02-27 |
| US9518096B2 (en) | 2016-12-13 |
| WO2010017542A1 (fr) | 2010-02-11 |
| CN102177233A (zh) | 2011-09-07 |
| EP3382011A1 (fr) | 2018-10-03 |
| AU2009279456B2 (en) | 2015-02-05 |
| DK2324113T3 (en) | 2018-04-16 |
| EP2324113B8 (fr) | 2018-04-04 |
| US20110195113A1 (en) | 2011-08-11 |
| JP6448445B2 (ja) | 2019-01-09 |